{ "meta": { "data_length": 2, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A108", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004195, "timestamp_received": "2026-09-25T01:17:03.052234+00:00Z", "timestamp_returned": "2026-09-25T01:17:03.056429+00:00Z", "trace_id": "9cd1c81c-2175-4cb3-9944-440a8e0b48e0" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:imfinzi:0:4", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "contributions": [ { "id": "ctrb:vanallenlab:2025-01-10:0", "type": "Contribution", "description": "Additional FDA approvals for initial version", "date": "2025-01-10", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2022-11-10:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2022-11-10", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:imfinzi", "type": "Document", "documentType": "Regulatory approval", "name": "Imfinzi (durvalumab) [package insert]. FDA.", "title": null, "aliases": [], "description": "AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "AstraZeneca UK Limited.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Imfinzi", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "durvalumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2017-05-01", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 761069, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-08-15", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:108", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:NSCLC", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC" ] } }, "objectTherapeutic": { "id": "txgrp:24", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C103194", "conceptType": "Therapy", "name": "Durvalumab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1919503", "code": "1919503", "name": "durvalumab", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1919503" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1594034", "code": "1594034", "name": "durvalumab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1594034" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:735230005", "code": "735230005", "name": "Durvalumab", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=735230005&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:42536415", "code": "42536415", "name": "Durvalumab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/42536415" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "PD-1/PD-L1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194" ] } }, { "id": "tx:ncit:C49085", "conceptType": "Therapy", "name": "Tremelimumab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2619313", "code": "2619313", "name": "tremelimumab", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2619313" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:741851", "code": "741851", "name": "tremelimumab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/741851" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:2054101000122107", "code": "2054101000122107", "name": "Tremelimumab", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=2054101000122107&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1450218", "code": "1450218", "name": "Tremelimumab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1450218" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "CTLA-4 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C49085", "code": "C49085", "name": "Tremelimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085" ] } }, { "id": "tx:ncit:C2688", "conceptType": "Therapy", "name": "Nab-paclitaxel", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:486610", "code": "486610", "name": "paclitaxel protein-bound", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=486610" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:19112933", "code": "19112933", "name": "paclitaxel protein-bound", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/19112933" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Taxane-based chemotherapy" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C2688", "code": "C2688", "name": "Nab-paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688" ] } }, { "id": "tx:ncit:C1282", "conceptType": "Therapy", "name": "Carboplatin", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:40048", "code": "40048", "name": "carboplatin", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=40048" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4299846", "code": "4299846", "name": "Carboplatin", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4299846" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:386905002", "code": "386905002", "name": "Carboplatin", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=386905002&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1344905", "code": "1344905", "name": "carboplatin", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1344905" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Platinum-based chemotherapy" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:34", "present": true, "subject": { "id": "bmkr:34", "type": "CategoricalVariant", "name": "Wild type ALK", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_004295.2, the protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5).", "digest": "o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ", "sequenceReference": { "id": "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs", "type": "SequenceReference", "name": "NP_004295.2", "aliases": [ "ensembl:ENSP00000373700.3", "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs", "refseq:NP_004295.2" ], "description": "The protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5), corresponding to the Refseq protein accession NP_004295.2.", "moleculeType": "protein", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs", "residueAlphabet": "aa" }, "start": 0, "end": 1620, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:427", "conceptType": "Gene", "name": "ALK", "primaryCoding": { "id": "coding:hgnc:427", "code": "HGNC:427", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000171094", "code": "ENSG00000171094", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000171094" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:238", "code": "238", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/238" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004304.5", "code": "NM_004304.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Wild type" } ] } }, { "id": "bmkr.criterion:35", "present": true, "subject": { "id": "bmkr:35", "type": "CategoricalVariant", "name": "Wild type EGFR", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_005219.2, the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5).", "digest": "gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt", "sequenceReference": { "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "type": "SequenceReference", "name": "NP_005219.2", "aliases": [ "ensembl:ENSP00000275493.2", "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "refseq:NP_005219.2" ], "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.", "moleculeType": "protein", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "residueAlphabet": "aa" }, "start": 0, "end": 1210, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3236", "conceptType": "Gene", "name": "EGFR", "primaryCoding": { "id": "coding:hgnc:3236", "code": "HGNC:3236", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000146648", "code": "ENSG00000146648", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000146648" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:1956", "code": "1956", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/1956" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005228.5", "code": "NM_005228.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Wild type" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:imfinzi:0", "type": "Indication", "description": "IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations.", "contributions": [ { "id": "ctrb:vanallenlab:2025-01-10:0", "type": "Contribution", "description": "Additional FDA approvals for initial version", "date": "2025-01-10", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2022-11-10:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2022-11-10", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:imfinzi", "type": "Document", "documentType": "Regulatory approval", "name": "Imfinzi (durvalumab) [package insert]. FDA.", "title": null, "aliases": [], "description": "AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "AstraZeneca UK Limited.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Imfinzi", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "durvalumab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2017-05-01", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 761069, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-08-15", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] }, { "id": "stmt:fda:imjudo:0:4", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "contributions": [ { "id": "ctrb:vanallenlab:2025-01-10:0", "type": "Contribution", "description": "Additional FDA approvals for initial version", "date": "2025-01-10", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2022-11-10:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2022-11-10", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:imjudo", "type": "Document", "documentType": "Regulatory approval", "name": "Imjudo (tremelimumab-actl) [package insert]. FDA.", "title": null, "aliases": [], "description": "AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "AstraZeneca AB.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Imjudo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "tremelimumab-actl", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 761270, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2022-11-10", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:108", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:NSCLC", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC" ] } }, "objectTherapeutic": { "id": "txgrp:24", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C103194", "conceptType": "Therapy", "name": "Durvalumab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1919503", "code": "1919503", "name": "durvalumab", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1919503" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1594034", "code": "1594034", "name": "durvalumab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1594034" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:735230005", "code": "735230005", "name": "Durvalumab", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=735230005&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:42536415", "code": "42536415", "name": "Durvalumab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/42536415" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "PD-1/PD-L1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194" ] } }, { "id": "tx:ncit:C49085", "conceptType": "Therapy", "name": "Tremelimumab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2619313", "code": "2619313", "name": "tremelimumab", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2619313" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:741851", "code": "741851", "name": "tremelimumab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/741851" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:2054101000122107", "code": "2054101000122107", "name": "Tremelimumab", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=2054101000122107&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1450218", "code": "1450218", "name": "Tremelimumab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1450218" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "CTLA-4 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C49085", "code": "C49085", "name": "Tremelimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085" ] } }, { "id": "tx:ncit:C2688", "conceptType": "Therapy", "name": "Nab-paclitaxel", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:486610", "code": "486610", "name": "paclitaxel protein-bound", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=486610" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:19112933", "code": "19112933", "name": "paclitaxel protein-bound", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/19112933" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Taxane-based chemotherapy" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C2688", "code": "C2688", "name": "Nab-paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688" ] } }, { "id": "tx:ncit:C1282", "conceptType": "Therapy", "name": "Carboplatin", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:40048", "code": "40048", "name": "carboplatin", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=40048" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4299846", "code": "4299846", "name": "Carboplatin", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4299846" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:386905002", "code": "386905002", "name": "Carboplatin", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=386905002&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1344905", "code": "1344905", "name": "carboplatin", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1344905" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Platinum-based chemotherapy" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:34", "present": true, "subject": { "id": "bmkr:34", "type": "CategoricalVariant", "name": "Wild type ALK", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_004295.2, the protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5).", "digest": "o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ", "sequenceReference": { "id": "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs", "type": "SequenceReference", "name": "NP_004295.2", "aliases": [ "ensembl:ENSP00000373700.3", "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs", "refseq:NP_004295.2" ], "description": "The protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5), corresponding to the Refseq protein accession NP_004295.2.", "moleculeType": "protein", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs", "residueAlphabet": "aa" }, "start": 0, "end": 1620, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:427", "conceptType": "Gene", "name": "ALK", "primaryCoding": { "id": "coding:hgnc:427", "code": "HGNC:427", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000171094", "code": "ENSG00000171094", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000171094" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:238", "code": "238", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/238" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004304.5", "code": "NM_004304.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Wild type" } ] } }, { "id": "bmkr.criterion:35", "present": true, "subject": { "id": "bmkr:35", "type": "CategoricalVariant", "name": "Wild type EGFR", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_005219.2, the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5).", "digest": "gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt", "sequenceReference": { "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "type": "SequenceReference", "name": "NP_005219.2", "aliases": [ "ensembl:ENSP00000275493.2", "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "refseq:NP_005219.2" ], "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.", "moleculeType": "protein", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "residueAlphabet": "aa" }, "start": 0, "end": 1210, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3236", "conceptType": "Gene", "name": "EGFR", "primaryCoding": { "id": "coding:hgnc:3236", "code": "HGNC:3236", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000146648", "code": "ENSG00000146648", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000146648" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:1956", "code": "1956", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/1956" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005228.5", "code": "NM_005228.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Wild type" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:imjudo:0", "type": "Indication", "description": "IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.", "contributions": [ { "id": "ctrb:vanallenlab:2025-01-10:0", "type": "Contribution", "description": "Additional FDA approvals for initial version", "date": "2025-01-10", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2022-11-10:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2022-11-10", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:imjudo", "type": "Document", "documentType": "Regulatory approval", "name": "Imjudo (tremelimumab-actl) [package insert]. FDA.", "title": null, "aliases": [], "description": "AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "AstraZeneca AB.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Imjudo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "tremelimumab-actl", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 761270, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2022-11-10", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }